Hyperliquid defies the market by riding the AI giant IPO boom, with HYPE surging 69% year-to-date
BlockBeats reported on May 18 that Hyperliquid's platform token HYPE rose against the market trend despite a broader crypto market downturn, gaining over 5% in the past 24 hours and achieving a cumulative increase of 69% this year. Market attention is focused on its HIP-3 pre-IPO perpetual contract ecosystem, with related trading volume surpassing $120 billion.
According to reports, Hyperliquid has launched pre-listing perpetual contracts for popular AI companies' IPOs, such as SpaceX, Anthropic, and OpenAI. Among these, the Cerebras perpetual contract introduced by TradeXYZ showed only about a 3% difference from the Nasdaq opening price, while traditional secondary market quotes had deviations as high as 35%.
Currently, the SpaceX pre-IPO contract SPCX is live on Hyperliquid, with a reference valuation of approximately $1.78 trillion. Market expectations suggest SpaceX's IPO may raise $75–80 billion, while valuations for Anthropic and OpenAI are also targeting the $1 trillion range.
Analysts believe that the HIP-3 model allows retail investors to participate in pre-IPO price discovery for major tech companies through on-chain markets for the first time, but it may also face regulatory scrutiny from US authorities regarding "unregistered securities exposure."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US wireless communications company Patriot Mobile (PTRT.US) applies for US listing, plans to raise 10 million dollars.
The wireless communications company Patriot Mobile, which focuses on serving Christian conservative organizations, filed documents with the U.S. Securities and Exchange Commission (SEC) last Friday to raise up to 10 million dollars through an initial public offering (IPO).
Valerio Therapeutics completes acquisition of Etherna Immunotherapies
